Search

Legend Biotech Corp ADR

Închisă

SectorSănătate

20.85 -4.45

Rezumat

Modificarea prețului

24h

Curent

Minim

21.64

Maxim

21.99

Indicatori cheie

By Trading Economics

Venit

88M

33M

Vânzări

82M

388M

EPS

0.09

Marjă de profit

8.568

Angajați

3,200

EBITDA

92M

60M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+120.3% upside

Dividende

By Acuity

Următoarele câștiguri

11 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

4.9M

4B

Deschiderea anterioară

25.3

Închiderea anterioară

20.85

Sentimentul știrilor

By Acuity

100%

0%

328 / 340 Clasament în Healthcare

Legend Biotech Corp ADR Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 aug. 2026, 23:01 UTC

Legend Biotech Corp shares are higher in after-market trading, maintaining a position near the upper end of their one-month trading range.

20 aug. 2026, 23:46 UTC

Legend Biotech Corp. shares are trading higher in after-market hours, diverging from broader market pressures amid rising crude oil prices and geopolitical tensions.

19 aug. 2026, 23:01 UTC

Legend Biotech Corp shares are higher in after-market trading, showing notable strength and exceeding the 20-day moving average. No specific news was identified.

18 aug. 2026, 20:03 UTC

Social Media

Legend Biotech Corp shares are higher today, buoyed by strong investor sentiment and analyst confidence in significant upside potential for the stock.

14 aug. 2026, 19:36 UTC

Shares of Legend Biotech Corp are trading higher, though fluctuations have been routine during the session. The stock remains below its 20-day moving average.

13 aug. 2026, 23:21 UTC

Legend Biotech Corp shares are higher in after-market hours, gaining traction following notable trading activity after Thursday's close. No specific news was identified.

12 aug. 2026, 23:16 UTC

Legend Biotech Corp. shares are higher in after-market hours, reflecting positive market conditions amid a Consumer Price Index report that met forecasts.

11 aug. 2026, 23:46 UTC

Shares of Legend Biotech Corp are higher in after-market hours, maintaining a position above the 20-day moving average amid stable trading conditions.

10 aug. 2026, 23:06 UTC

Shares of Legend Biotech are higher in after-market trading, settling above Monday's close despite mixed market sentiment and geopolitical tensions.

7 aug. 2026, 23:46 UTC

Shares of Legend Biotech Corp traded higher in after-market hours, amid a broader market context of a declining unemployment rate.

6 aug. 2026, 20:06 UTC

Legend Biotech Corp shares are higher today, reflecting a shift from recent trends. No specific company news was identified to explain this movement.

4 aug. 2026, 19:36 UTC

Legend Biotech Corp shares are higher today, recovering from an earlier low. Positive momentum persists despite a decline in U.S. core factory orders.

3 aug. 2026, 22:01 UTC

Shares of Legend Biotech Corp are higher in after-market trading, reflecting gains since Monday's close amid broader market advances in tech and oil-sensitive sectors.

31 iul. 2026, 23:56 UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

30 iul. 2026, 22:41 UTC

Shares of Legend Biotech Corp are trading lower in after-market hours, continuing a trend of unusual weakness since Thursday's close.

29 iul. 2026, 19:27 UTC

Social Media

Legend Biotech Corp shares are lower, extending a four-session decline. Raymond James projects a 12-month price target range of $58 to $86.

28 iul. 2026, 22:56 UTC

Shares of Legend Biotech Corp are trading higher in after-market hours, despite no specific news identified. The broader market showed gains earlier in the day.

27 iul. 2026, 23:16 UTC

Legend Biotech Corp shares are higher in after-market hours, having briefly reached a session high. The price remains below its 20-day moving average.

24 iul. 2026, 19:16 UTC

News

UBS downgraded Legend Biotech Corp to Neutral and cut its price target to $28, contributing to a decline in shares during Friday's session.

22 iul. 2026, 18:31 UTC

Legend Biotech Corp shares are lower today amid broader market weakness and rising geopolitical tensions, despite an earlier peak during the session.

21 iul. 2026, 16:46 UTC

Legend Biotech Corp. shares are higher today, reaching a session peak amid rising crude oil prices, despite trading below its 20-day moving average.

20 iul. 2026, 19:01 UTC

Legend Biotech Corp is trading higher during Monday's session, rebounding from an earlier low and showing strength after a week of declines.

Comparație

Modificare preț

Legend Biotech Corp ADR Așteptări

Obiectiv de preț

By TipRanks

120.3% sus

Prognoză pe 12 luni

Medie 48.07 USD  120.3%

Maxim 78 USD

Minim 24 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLegend Biotech Corp ADR - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

10 ratings

6

Cumpărare

4

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.
help-icon Live chat